Wed, June 21, 2023

Charles Duncan Reiterated (XENE) at Buy and Held Target at $58 on, Jun 21st, 2023

  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. -buy-and-held-target-at-58-on-jun-21st-2023.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
  • 🞛 This publication is a summary or evaluation of another publication
  • 🞛 This publication contains potentially derogatory content such as foul language or violent themes
Charles Duncan of Cantor Fitzgerald, Reiterated "Xenon Pharmaceuticals Inc." (XENE) at Buy and Held Target at $58 on, Jun 21st, 2023.

Charles has made no other calls on XENE in the last 4 months.



There are 5 other peers that have a rating on XENE. Out of the 5 peers that are also analyzing XENE, 0 agree with Charles's Rating of Hold.



These are the ratings of the 5 analyists that currently disagree with Charles


  • Yatin Suneja of "Guggenheim" Reiterated at Strong Buy and Held Target at $49 on, Thursday, June 15th, 2023
  • Laura Chico of "Wedbush" Maintained at Buy with Increased Target to $47 on, Wednesday, May 10th, 2023
  • Tessa Romero of "JP Morgan" Maintained at Buy with Increased Target to $55 on, Tuesday, April 25th, 2023
  • Serge Belanger of "Needham" Reiterated at Strong Buy and Held Target at $50 on, Friday, April 21st, 2023
  • Brian Abrahams of "RBC Capital" Reiterated at Buy and Held Target at $51 on, Wednesday, March 22nd, 2023